Biogen Medical Research
Immunology
Scientific Objectives
At this time, Biogen is primarily considering investigator-sponsored Collaborative Research proposals – should you have a study that fits these areas of interest where Biogen’s input on the design could be considered, please feel free to contact medicalresearch@biogen.com or your assigned Biogen Medical Science Liaison to discuss your idea and timeline to submit.
- Lupus
- Pathogenesis:
- Interferon, myeloid cell biology in autoimmunity and inflammatory disease
- Biomarkers of disease activity and treatment response
- Socio-economic burden: systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) health disparity and unmet need in real world
- Treatment patterns and sequencing:
- Real world evidence (RWE) for organ domain specific disease burden
- Burden of standard of care, corticosteroid tapering and steroid-sparing strategies
- Patient centered outcomes including fatigue and cognitive dysfunction
- AI in image analysis and diagnosis of CLE
- Skin of color and CLE - RWE retrospective/prospective studies
- Characterization of CLE subtypes in the clinic
- Pathogenesis:
- Transplant
- Antibody-mediated rejection (AMR) and microvascular inflammation (MVI)
- Evaluation of mechanisms in the pathogenesis and pathophysiology of AMR or MVI
- Use of clinical biomarkers or novel strategies to identify patients with AMR or MVI
- Long-term outcomes associated with clinical, histologic, and molecular features of AMR or MVI
- Studies evaluating healthcare-resource utilization or patient-centered outcomes related to AMR or MVI
- Studies identifying socioeconomic and demographic factors associated with barriers to healthcare access among kidney transplant recipients
- Antibody-mediated rejection (AMR) and microvascular inflammation (MVI)
Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee support will be awarded.